Search
Raltegravir
go.drugbank.com/drugs/DB06817ApprovedInvestigationalFood and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. … Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S.
Categories: Heterocyclic Compounds, 1-Ring, Antivirals used in combination for the treatment of HIV infectionsProducts: ISENTRESS® TABLETAS MASTICABLES 25 MG, ISENTRESS® GRÁNULOS PARA SUSPENSIÓN ORAL 100 MGLanthanum carbonate
go.drugbank.com/drugs/DB06792ApprovedIt is a large pill that requires thorough chewing to avoid choking and other gastrointestinal adverse effects. … Lanthanum carbonate is a phosphate binder marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals.
Synonyms: Lanthanum(3+) carbonateProducts: FOSRENOL 500 MG, FOSRENOL 750 MG.Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalDacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible … binding at the ATP domain of the epidermal growth factor receptor family kinase domains.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexProducts: Vizimpro 15 mg Film-Coated Tablets, VİZİMPRO 15 MG FİLM KAPLI TABLET, 30 ADETDeficiency of the interleukin-1 receptor antagonist
go.drugbank.com/conditions/DBCOND0008480Synonyms: Deficiency of interleukin-1 receptor antagonist, Interleukin-1 receptor antagonist deficiencyPrimary Insulin-Like Growth Factor-1 Deficiency
go.drugbank.com/conditions/DBCOND0041585Synonyms: Primary insulin like growth factor-1 deficiency, Primary Insulin-Like Growth Factor-1 DeficiencyAbemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalAbemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity … It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with [DB00947].
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, MATE 1 InhibitorsProducts: VERZENIO® 100 MG, VERZENIO® 150 MGBezafibrate
go.drugbank.com/drugs/DB01393ApprovedInvestigationalIt decreases low density lipoproteins and increases high density lipoproteins.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsSynonyms: 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acidDL-alpha tocopheryl acetate
go.drugbank.com/drugs/DB14477ApprovedMixtures: Vitamins A, C & E Cap., Folika-MGCategories: Vitamin ECenobamate
go.drugbank.com/drugs/DB06119ApprovedInvestigational[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABA<sub>A</sub> and inhibits voltage gated sodium channels. … [L10653] Cenobamate was granted FDA approval on 21 November 2019.[L10653]
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 SubstratesProducts: XCOPRI TITRATION PACK 50 mg, 100 mg, XCOPRI TITRATION PACK 12.5 mg, 25 mgUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalUpadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. … [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsProducts: RİNVOQ 15 MG UZATILMIŞ SALIMLI TABLET, 98 ADET, RİNVOQ 15 MG UZATILMIŞ SALIMLI TABLET, 28 ADET